These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 6161534)

  • 21. Comparison of the pharmacokinetic and pharmacodynamic properties of procainamide and N-acetylprocainamide.
    Atkinson AJ; Ruo TI; Piergies AA
    Angiology; 1988 Jul; 39(7 Pt 2):655-67. PubMed ID: 2457345
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative antiarrhythmic efficacy of intravenous N-acetylprocainamide and procainamide.
    Sonnhag C; Karlsson E
    Eur J Clin Pharmacol; 1979 Jun; 15(5):311-7. PubMed ID: 378673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. N-acetylprocainamide kinetics during intravenous infusions and subsequent oral doses in patients with coronary artery disease and ventricular arrhythmias.
    Ludden TM; Crawford MH; Kennedy GT
    Pharmacotherapy; 1985; 5(1):11-5. PubMed ID: 2580291
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic studies of procainamide (PA) and N-acetylprocainamide (NAPA) in healthy subjects.
    Wierzchowiecki M; Michałowska D; Lowicki Z; Ochotny R; Grześkowiak A; Tomaszkiewicz T
    Int J Clin Pharmacol Ther Toxicol; 1980 Jun; 18(6):272-6. PubMed ID: 6161089
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term antiarrhythmic therapy with N-acetylprocainamide.
    Lertora JJ; Atkinson AJ; Kushner W; Nevin MJ; Lee WK; Jones C; Schmid FR
    Clin Pharmacol Ther; 1979 Mar; 25(3):273-82. PubMed ID: 310748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. N-acetylprocainamide's antiarrhythmic action in patients with ventricular tachycardia.
    Somberg J; Wynn J; Miura D; Torres V; Williams S; Keefe D
    Angiology; 1986 Dec; 37(12 Pt 2):972-81. PubMed ID: 2433972
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma concentrations of desethyl N-acetylprocainamide in patients treated with procainamide and N-acetylprocainamide.
    Ruo TI; Thenot JP; Stec GP; Atkinson AJ
    Ther Drug Monit; 1981; 3(3):231-7. PubMed ID: 6172888
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy, plasma concentrations and adverse effects of a new sustained release procainamide preparation.
    Giardina EG; Fenster PE; Bigger JT; Mayersohn M; Perrier D; Marcus FI
    Am J Cardiol; 1980 Nov; 46(5):855-62. PubMed ID: 6159783
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiarrhythmic potency of N-acetylprocainamide.
    Elson J; Strong JM; Lee WK; Atkinson AJ
    Clin Pharmacol Ther; 1975 Feb; 17(2):134-40. PubMed ID: 1122675
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kinetics of N-acetylprocainamide deacetylation.
    Stec GP; Ruo TI; Thenot JP; Atkinson AJ; Morita Y; Lertora JJ
    Clin Pharmacol Ther; 1980 Nov; 28(5):659-66. PubMed ID: 6160014
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acecainide (N-acetylprocainamide). A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiac arrhythmias.
    Harron DW; Brogden RN
    Drugs; 1990 May; 39(5):720-40. PubMed ID: 1693889
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative effects of procainamide and its N-acetylated metabolite in conscious dogs with atrioventricular block: plasma concentration-response relationships.
    Boucher M; Dubray C; Paire M; Duchêne-Marullaz P
    J Cardiovasc Pharmacol; 1987 Nov; 10(5):562-7. PubMed ID: 2447406
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A new anti-arrhythmia drug. II. Comparative studies of the effects of a new acyl derivative of procainamide, procainamide and N-acetylprocainamide on blood pressure and the electrocardiogram in rabbits].
    Kusowska J
    Acta Pol Pharm; 1989; 46(1):90-7. PubMed ID: 2479226
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Circadian changes in procainamide and N-acetylprocainamide kinetics in the rat.
    Bruguerolle B; Jadot G
    J Pharm Pharmacol; 1985 Sep; 37(9):654-6. PubMed ID: 2416904
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Electrophysiologic effects of N-acetylprocainamide in human beings.
    Jaillon P; Rubenson D; Peters F; Mason JW; Winkle RA
    Am J Cardiol; 1981 May; 47(5):1134-40. PubMed ID: 6164285
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trimethoprim alters the disposition of procainamide and N-acetylprocainamide.
    Kosoglou T; Rocci ML; Vlasses PH
    Clin Pharmacol Ther; 1988 Oct; 44(4):467-77. PubMed ID: 2458879
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Electrophysiologic interactions of procainamide and N-acetylprocainamide in isolated canine cardiac Purkinje fibers.
    Coyle JD; Carnes CA; Schaal SF; Muir WW
    J Cardiovasc Pharmacol; 1992 Aug; 20(2):197-205. PubMed ID: 1381010
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cumulation of N-acetylprocainamide, an active metabolite of procainamide, in patients with impaired renal function.
    Drayer DE; Lowenthal DT; Woosley RL; Nies AS; Schwartz A; Reidenberg MM
    Clin Pharmacol Ther; 1977 Jul; 22(1):63-9. PubMed ID: 872496
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of N-acetylation of procainamide and renal clearance of N-acetylprocainamide by para-aminobenzoic acid in humans.
    Tisdale JE; Rudis MI; Padhi ID; Svensson CK; Webb CR; Borzak S; Ware JA; Krepostman A; Zarowitz BJ
    J Clin Pharmacol; 1995 Sep; 35(9):902-10. PubMed ID: 8786250
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of coronary artery ligation on the pharmacokinetics of N-acetylprocainamide in dogs.
    Lai CM; Reynolds RD; Kamath BL; Calzadilla S; Gupta SD; Look ZM; Yacobi A
    Res Commun Chem Pathol Pharmacol; 1980 Aug; 29(2):369-72. PubMed ID: 6158076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.